Intriguingly, the decline in new trials employing PD-1/PD-L1 inhibitors has been observed since 2022 in skin cancer, respiratory thoracic cancer, and head and neck cancer, while there has been an increase in breast cancer and digestive tract-associated cancers. This evidence concerns the gene CD274 and head and neck cancer.